跳到正文
TNW· Cristian Dina·· 2 天前精選AI 評分78

Isomorphic Labs 獲 Sequoia Capital、Greenoaks 領投 $5bn C 輪融資,推進 AI 藥物設計

Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design

AI 導讀

Isomorphic Labs 宣佈完成由 Greenoaks 和 Sequoia Capital 共同領投的 $5bn C 輪融資,Alphabet 亦持續大額投資。公司表示,資金將加快其邁向臨牀試驗,並用於由小分子藥物拓展至幾乎所有藥物形式,包括大分子生物製劑。其藥物設計引擎 IsoDDE 在自有腫瘤及免疫學項目和合作項目中取得正面的臨牀前結果,公司目前有 20 多個項目進行中。

推薦理由

這輪融資距公司 5 月完成 $2.1bn 融資僅六個月,資金將支持其加快邁向臨牀試驗,並擴展至大分子生物製劑等藥物形式。

正文 · 原文

Isomorphic Labs, the Alphabet drug discovery company run by Demis Hassabis, has raised $5bn in a Series C round co-led by Greenoaks and Sequoia Capital. The company announced the round on Tuesday, six months after it raised $2.1bn in May.

Andreessen Horowitz and several other new investors joined, with what Isomorphic called continued significant investment from Alphabet. All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic said investors oversubscribed the round.

The company did not disclose its valuation, Bloomberg reported. Bloomberg had reported this month that the round would value Isomorphic at about $50bn.

‘Hundreds of drugs a year’

Hassabis told Bloomberg’s Rebecca Torrence and Shirin Ghaffary that the money will speed up Isomorphic’s move towards clinical trials.

“What we’re trying to build is a platform to do hundreds of drugs a year,” Hassabis told Bloomberg.

Isomorphic said its drug design engine, IsoDDE, is producing positive preclinical results in its own oncology and immunology programmes and with partners. It has more than 20 programmes underway, Hassabis said. Its pharma partners include Eli Lilly, Novartis and Johnson & Johnson.

In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. He would not give Bloomberg an updated target. He said the company is on track with its regulatory submissions and will have more to announce in 2027. No regulator has yet approved an AI-designed drug, Bloomberg noted.

Isomorphic will also use the money to move beyond small-molecule drugs into “pretty much all modalities”, Hassabis said, including large-molecule biologics.

The backers

“Isomorphic Labs is building foundational technology for the future of medicine,” said Konstantine Buhler, a partner at Sequoia Capital.

Buhler told Bloomberg that Sequoia backed the company because Isomorphic has found scaling laws for its models. That means performance keeps improving with more computing power and data, he said.

The round is Isomorphic’s first since Hassabis stepped back as Google DeepMind’s chief executive in August, in an Alphabet shake-up. He is now DeepMind’s chair and Alphabet’s chief scientist, and remains Isomorphic’s chief executive.

He also addressed computing power. Jensen Huang’s resignation from Nvidia last week has some AI companies worried about their access to chips, Bloomberg reported. Google designs its own AI chips.

“We’ve got very secure compute pipelines,” Hassabis told Bloomberg.

Isomorphic started in 2021 to build on Google DeepMind’s AlphaFold protein structure model. It has its headquarters in London and offices in Cambridge, Massachusetts, and Lausanne.

來源:TNW · thenextweb.com